CN1706449A - Compound prepn of parasitic loranthus and mistletoe and preparing method thereof - Google Patents
Compound prepn of parasitic loranthus and mistletoe and preparing method thereof Download PDFInfo
- Publication number
- CN1706449A CN1706449A CN 200510026267 CN200510026267A CN1706449A CN 1706449 A CN1706449 A CN 1706449A CN 200510026267 CN200510026267 CN 200510026267 CN 200510026267 A CN200510026267 A CN 200510026267A CN 1706449 A CN1706449 A CN 1706449A
- Authority
- CN
- China
- Prior art keywords
- gram
- herba
- grams
- visci
- herba taxilli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine technology, and is especially one kind of compound Chinese medicine preparation with parasitic loranthus and mistletoe as main components as well as bletilla tuber, lily, loquat leaf and arborvidae leaf. The compound Chinese medicine may be prepared into oral liquid, capsule, tablet, granule or other form, and has the functions of resisting tuberculosis, resisting infection, clearing away lung heat, eliminating phlegm, moistening lung, etc. It may be used in treating tuberculosis, pulmonary heart disease, pneumonia, acute and chronic bronchitis and other respiratory system diseases and syndromes alone or together with other chemotherapeutic medicine and antibiotic, and is especially suitable for treatment of drug resisting tuberculosis.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the preparation method of a kind of Chinese medicine Herba Taxilli and Herba Visci compound preparation.
Background technology
Pulmonary tuberculosis is the very serious respiratory diseases of a kind of harm, so far seized countless people's life time immemorial, reasons such as tangible drug resistance had been produced in recent years owing to tubercule bacillus, pulmonary tuberculosis is the rise spreading trend in the world again, according to authoritative recent statistics: 1/3 population promptly about 1,700,000,000 people in the whole world infect the pulmonary tuberculosis pathogenic bacteria, and increase 9,000,000 every year newly, and annual death toll reaches about 3,000,000 people.Scholarly forecast: if do not take effective control measure, 10 years from now on, global number of the infected will reach 3,000,000,000.Therefore the phthisical revivable global serious public health problem that become.China is one of the high burden of whole world tuberculosis country, and the patient occupies the second place of the world, and the tubercle bacillus affection person is 1/3 about 400,000,000 people of national population, and the patient reaches 4,500,000, dies from number lungy every year and reaches 150,000.Phthisical traditional therapy is to adopt chemotherapeutics, the tool obvious toxic and side effects, and improper use easily produces drug resistance and lose should be effective in cure.Therefore the anxious development of new for the treatment of is treated phthisical active drug.
Summary of the invention
One object of the present invention is to provide compound Chinese medicinal preparation of being made up of Herba Taxilli and Herba Visci and preparation method thereof.
Herba Taxilli of the present invention and Herba Visci are the parasitics plants, are called " A Jiami " at the Chinese yunnan Dalibaizu.Wherein Herba Taxilli derives from parasitic any plant that belongs to (Taxillus Van Tiehg.), the parasitic genus of melonidum (Scurrula Linn.) or Loranthus (Loranthus Jacq.) of the blunt fruit of Loranthaceae (Loranthaceae), parasitic any plant that belongs to of preferably blunt fruit, the parasitic Herba Taxilli (Taxillus chinensis (DC.) Danser) that belongs to of most preferably blunt fruit.Wherein Herba Visci derives from any plant of Loranthaceae (Loranthaceae) Viscum (Viscum Linn.), preferably the Herba Visci of Viscum (Viscum coloratum (Komar.) Nakai).Scientific definition and category about Loranthaceae, the parasitic genus of blunt fruit, the parasitic genus of melonidum, Loranthus and Viscum, (Hou Kuanzhao compiles referring to " Chinese Higher plant section belongs to dictionary " (revised edition), Beijing: Science Press, 1984.12) and Chinese Plants will the 24th volume (Beijing: Science Press, 1986).As Herba Taxilli and the Herba Visci that compatibility is used, be generally the dry stem and branch with leaf of these plants.
Herba Taxilli provided by the present invention and Herba Visci compound Chinese medicinal preparation are to be the formulated compound preparation of monarch drug with Herba Taxilli, two kinds of medical materials of Herba Visci, and its composition and proportion compatibility are as follows:
Herba Taxilli 3-30 gram; Herba Visci 3-30 gram; Pseudobulbus Bletillae (Rhizoma Bletillae) 2-20 gram; Bulbus Lilii 2-20 gram; Folium Eriobotryae 1-10 gram; Cacumen Platycladi 1-10 gram.
The proportion compatibility of preferred compound preparation is as follows:
Herba Taxilli 6-15 gram; Herba Visci 6-15 gram; Pseudobulbus Bletillae (Rhizoma Bletillae) 4-10 gram; Bulbus Lilii 4-10 gram; Folium Eriobotryae 2-6 gram; Cacumen Platycladi 2-6 gram.
The proportion compatibility of typical compound preparation is as follows:
Herba Taxilli 9 grams; Herba Visci 9 grams; The Pseudobulbus Bletillae (Rhizoma Bletillae) 6 grams; Bulbus Lilii 6 grams; Folium Eriobotryae 3 grams; Cacumen Platycladi 3 grams.
The present invention deserves to be called and states compound preparation is " No. 1, A Jia miaow tuberculosis ".
The present invention also provides the preparation technology of above-mentioned compound preparation, and concrete steps are as follows:
With Herba Taxilli, Herba Visci, the Pseudobulbus Bletillae (Rhizoma Bletillae), Bulbus Lilii, Folium Eriobotryae, Cacumen Platycladi 6 flavor medical materials, the decocting that adding 6-12 doubly measures boils 2 times, each 1.5-2.5 hour, filter, merging filtrate is concentrated into proportion and is 1.05 concentrated solution, adds the fruit juice clarifier of 4-8% while stirring, leave standstill 6-10 hour after-filtration, get clear liquor.After clear liquor suitably concentrated, add adjuvant (as Mel, sugar, antiseptic, flavoring agent etc.) and be mixed with liquid preparations such as oral liquid; Or concentrated solution is prepared into powder with vacuum drying, spray drying or lyophilization, add necessary adjuvant (as Pulvis Talci, magnesium stearate, starch etc.) then and make solid dosage formss such as capsule, tablet, granule.
The present invention also provides the purposes of above-mentioned compound preparation.Said preparation has major functions such as anti-consumptive disease, antiinflammatory, infection, removing heat from the lung and dissipating phlegm, cough-relieving hemostasis, heart tonifying lung moistening, adjusting immunity, can share separately or with chemotherapeutic, antimicrobial drug, be used for the treatment of various respiratory systematic infection disease and syndromes such as pulmonary tuberculosis, pulmonary heart disease, pneumonia, acute/chronic bronchitis, be particularly useful for the treatment of drug resistance and drug resistant pulmonary tuberculosis, can play the effect of alleviating and reducing toxicity due to the chemotherapy and improve therapeutic effect.
The present invention adopts animal experiment method, has confirmed that above-mentioned compound preparation is to phthisical therapeutic effect.
The therapeutical effect of 1. pairs of m tuberculosis infection mouse experiments of test example pulmonary tuberculosis model
One, material and method
1 supplies the reagent thing:
Compound recipe is formed: Herba Taxilli 9 grams; Herba Visci 9 grams; The Pseudobulbus Bletillae (Rhizoma Bletillae) 6 grams; Bulbus Lilii 6 grams; Folium Eriobotryae 3 grams; Cacumen Platycladi 3 grams
Method for making: above-mentioned 6 flavors, add water 350mL and decoct secondary, each 1.5 hours, merge decocting liquid, put cold after-filtration, clear liquor concentrates the final vacuum drying, gets dried powder, and is standby.
The contrast medicine: isoniazid, produce (pure powder) by Yongkang, Beijing pharmaceutical factory
2 animals: Kunming mouse is provided by Chinese Academy of Medical Sciences's experimental animal room, 120 male and female half and half, and body weight 20-22g/ is only.
3 bacterial strains: Mycobacterium tuberculosis H
37RV, strain number (93009) is provided by Nat'l Pharmaceutical ﹠ Biological Products Control Institute.
4 experimental techniques:
(1) attacks the bacterium preparation: get the H that is seeded in 3 weeks of growth on the Russell medium
37It is standby that the lawn of RV (93009) strain grinds to form 5mg/ml bacterium liquid with agate mortar.
(2) attack molding:
Model control group: totally two groups, every group of 20 mices are shot molding by a 1mg bacterium liquid/vein for the 1st group, shoot molding by a 0.75mg bacterium liquid/abdominal cavity for 1 group in addition.
The administration group: divide three groups, every group of 20 mices are shot molding by a 0.75mg bacterium liquid/abdominal cavity;
The chemotherapy matched group: one group, 20 mices are shot molding by a 0.75mg bacterium liquid/abdominal cavity;
(3) administering mode:
Model control group: attack and give the normal saline oral medication back next day.
Chemotherapy matched group: attack and give isoniazid 0.02g/kg, oral medication after three days.
Organized by examination: high dose group 3.92g/kg extract;
Middle dosage group 1.546g/kg extract;
Low dose group 0.773g/kg extract;
All beginning administration in the 2nd day finishes until experiment after attacking molding.
5. observation index:
(1) the half death time; (2) (lung) organ index; (3) (lung) pathological analysis; (4) (lung) bacterium separation number
6. the result judges:
(1) the half death time: the results are shown in Table 1.
When table 1. half is dead
| Grouping | Challenge dose | Therapeutic dose | Death toll/survival number | The half dead time (my god) | ?P |
| Model group model group chemotherapy group is subjected to examination group height to be subjected to be subjected in the examination group examination group low | 1mg/ 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ only | ??0g/kg ??0g/kg ??0.02g/kg ??3.92g/kg ??1.55g/kg ??0.77g/kg | ??10/10 ??8/12 ??0/20 ??4/16 ??9/11 ??8/12 | ??18 ??＞60 ??＞60 ??＞60 ??＞60 ??＞60 | ?? ????? ?＜0.001 ?＜0.001 |
Conclusion: high dose compound recipe administration group and chemotherapy group can be seen obvious therapeutic effect under identical attack microbial inoculum amount, with model control group comparison chemotherapy group with tried high dose group P＜0.001.
(2) (lung) organ index: the results are shown in Table 2.
Conclusion: (lung) organ index of administration group is better than model control group slightly, but there was no significant difference, and chemotherapy group tool significant difference (P＜0.005)
(3) (lung) pathological analysis: the results are shown in accompanying drawing and table 3.
Conclusion: with model control group comparison chemotherapy group with tried the high dose group lung tissue and do not have tuberculosis specific lesions and cheesy necrosis tubercle.
Table 2. (lung) organ index
| Grouping (P) | Challenge dose | Therapeutic dose | (lung) | Organ index |
| Model group model group chemotherapy group is subjected to examination group height to be subjected to be subjected in the examination group examination group low | 1mg/ 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ only | ??0g/kg ??0g/kg ??0.02g/kg ??3.92g/kg ??1.55g/kg ??0.77g/kg | ? ??25 ??5 ??22 ??21 ??22 | ? ??? ???? ??＜0.005 |
Table 3. (lung) pathological analysis
| Grouping | Challenge dose | Therapeutic dose | Pathologic condition under (lung) mirror |
| The model group chemotherapy group is subjected to examination group height to be subjected to be subjected in the examination group examination group low | 0.75mg/ only 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ only | ??0g/kg ??0.02g/kg ??3.92g/kg ??1.55g/kg ??0.77g/kg | Do not have the tuberculosis specific lesions with the cheesy necrosis tubercle and do not have the tuberculosis specific lesions, 2 following proliferative lesser tubercle with the cheesy necrosis tubercle with the cheesy necrosis tubercle |
(4) (lung) bacterium separation number: the results are shown in Table 4.
Table 4 (lung) bacterium separation number
| Challenge dose | Therapeutic dose | (lung) bacterium separation number | Logarithm value | ?P | |
| The model group chemotherapy group is subjected to examination group height to be subjected to be subjected in the examination group examination group low | 0.75mg/ only 0.75mg/ 0.75mg/ 0.75mg/ 0.75mg/ only | ??0g/kg ??0.02g/kg ??3.92g/kg ??1.55g/kg ??0.77g/kg | ??10 8??10 2??2.9 4??10 8??10 8 | ??6.5 ??0.839 ??3.0013 ??6.70 ??6.50 | ???? ?＜0.001 ?＜0.001 |
Conclusion: all separate accessory significant difference P＜0.001 with high dose administration group lung with model control group comparison chemotherapy group.
7. conclusion: the mouse lung nuclear tests model that this compound preparation water extract high dose administration (3.92g/kg) is attacked low bacterium amount (0.75mg/ only) has obvious treatment meaning.
The inventor once utilized above-mentioned compound preparation to treat the pulmonary tuberculosis patient of thousands of examples, had all obtained satisfactory effect.
Description of drawings
Accompanying drawing 1 is dissected photo for compound preparation of the present invention to the therapeutical effect internal organs of m tuberculosis infection mouse experiment pulmonary tuberculosis model.Wherein, (lung tissue presents pale pink to Fig. 1 (1) for normal group-lung, no tuberculosis), Fig. 1 (2) is the model lung, spleen (visible a plurality of point-like nodositas agglomerates and brown tuberculous foci in the lung tissue), Fig. 1 (3) is that (no lumps thing and brown change chemotherapy lung in the lung, color is with normally similar), Fig. 1 (4) is heavy dose of lung (the no agglomerate tuberosity in the lung of Chinese medicine, there is a small amount of less brown to change, color and normal group are similar), Fig. 1 (5) is middle dosage lung (no agglomerate tuberosity in the lung has a large amount of less brown to change), Fig. 1 (6) is low dose of lung (no agglomerate tuberosity in the lung has a large amount of less brown to change).
The specific embodiment
Embodiment 1: the preparation and the application thereof of compound preparation (decocting liquid)
Prescription is formed: Herba Taxilli, each 9 gram of Herba Visci; The Pseudobulbus Bletillae (Rhizoma Bletillae), each 6 gram of Bulbus Lilii; Folium Eriobotryae, each 3 gram of Cacumen Platycladi.
Purposes: respiratory disorders such as New Development or recurrent pulmonary tuberculosis, pulmonary heart disease, pneumonia, acute/chronic bronchitis.
Usage: adult's potion every day, with 500mL decocting 2 times, each 1.5 hours, merge decocting liquid, divide 2-3 time oral.Be a course of treatment January continuously.
Embodiment 2: the preparation and the application thereof of compound preparation (capsule)
Prescription is formed: Herba Taxilli, each 900 gram of Herba Visci; The Pseudobulbus Bletillae (Rhizoma Bletillae), each 650 gram of Bulbus Lilii; Folium Eriobotryae, each 400 gram of Cacumen Platycladi.
Method for making: above 6 flavors, add 18 liters in water and decoct 2 times, each 2 hours, filter, merging filtrate is concentrated into proportion and is 1.05 concentrated solution, adds 5% fruit juice clarifier while stirring, leaves standstill 8 hours after-filtration, clear liquor.Clear liquor is concentrated and vacuum drying, get " No. 1, A Jia miaow tuberculosis " hot water extract, this extract is ground into fine powder, load No. 0 capsule, specification 0.5g/ grain, promptly.
Purposes: respiratory disorders such as New Development or recurrent pulmonary tuberculosis, pulmonary heart disease, pneumonia, acute/chronic bronchitis.
Usage: adult every day 3 times, each 2-3 grain.Be a course of treatment January continuously.
Embodiment 3: the preparation and the application thereof of compound preparation (oral liquid)
Prescription is formed: Herba Taxilli, each 1000 gram of Herba Visci; The Pseudobulbus Bletillae (Rhizoma Bletillae), each 600 gram of Bulbus Lilii; Folium Eriobotryae, each 300 gram of Cacumen Platycladi.
Method for making: above 6 flavors, add 18 liters in water and decoct 2 times, each 2 hours, filter, merging filtrate is concentrated into proportion and is 1.05 concentrated solution, adds 5% fruit juice clarifier while stirring, leaves standstill 8 hours after-filtration, clear liquor.Clear liquor is condensed into the thick extractum of proportion 1.10-1.15, adds 20% refined honey, be distributed into the 20mL/ bottle after fully stirring, promptly.
Purposes: respiratory disorders such as New Development or recurrent pulmonary tuberculosis, pulmonary heart disease, pneumonia, acute/chronic bronchitis.
Usage: adult every day 3 times, each 20mL.Be a course of treatment January continuously.
Above-mentioned various prescription is through using the therapeutic effect that all has very.The actual use shows that the compound preparation in proportion compatibility scope of the present invention all has excellent curative, differs here one to enumerate.
Claims (5)
1, a kind of Herba Taxilli and Herba Visci compound Chinese medicinal preparation is characterized in that with Herba Taxilli and two kinds of Chinese medicines of Herba Visci being that the monarch drug compatibility is formed, and its proportion compatibility is as follows:
Herba Taxilli 3-30 gram; Herba Visci 3-30 gram; Pseudobulbus Bletillae (Rhizoma Bletillae) 2-20 gram; Bulbus Lilii 2-20 gram; Folium Eriobotryae 1-10 gram; Cacumen Platycladi 1-10 gram.
2, compound preparation according to claim 1 is characterized in that proportion compatibility is as follows:
Herba Taxilli 6-15 gram; Herba Visci 6-15 gram; Pseudobulbus Bletillae (Rhizoma Bletillae) 4-10 gram; Bulbus Lilii 4-10 gram; Folium Eriobotryae 2-6 gram; Cacumen Platycladi 2-6 gram.
3, compound preparation according to claim 1 is characterized in that proportion compatibility is as follows:
Herba Taxilli 9 grams; Herba Visci 9 grams; The Pseudobulbus Bletillae (Rhizoma Bletillae) 6 grams; Bulbus Lilii 6 grams; Folium Eriobotryae 3 grams; Cacumen Platycladi 3 grams.
4, a kind of preparation method as compound preparation as described in one of claim 1-3, it is characterized in that concrete steps are as follows: with Herba Taxilli, Herba Visci, the Pseudobulbus Bletillae (Rhizoma Bletillae), Bulbus Lilii, Folium Eriobotryae, Cacumen Platycladi 6 flavor medical materials, the decocting that adding 6-12 doubly measures boils 2 times, each 1.5-2.5 hour, filter merging filtrate, be concentrated into proportion and be 1.05 concentrated solution, the fruit juice clarifier that adds 4-8% while stirring leaves standstill 6-10 hour after-filtration, gets clear liquor; After clear liquor suitably concentrated, add adjuvant and be mixed with liquid preparations such as oral liquid; Or concentrated solution is prepared into powder with vacuum drying, spray drying or lyophilization, add necessary adjuvant then and make solid dosage formss such as capsule, tablet, granule.
5, the application in treatment pulmonary tuberculosis, pulmonary heart disease, pneumonia, acute/chronic bronchitis disease as described Herba Taxilli of one of claim 1-3 and Herba Visci compound preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510026267 CN1706449B (en) | 2005-05-27 | 2005-05-27 | Compound preparation of parasitic loranthus and mistletoe and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510026267 CN1706449B (en) | 2005-05-27 | 2005-05-27 | Compound preparation of parasitic loranthus and mistletoe and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1706449A true CN1706449A (en) | 2005-12-14 |
| CN1706449B CN1706449B (en) | 2010-11-17 |
Family
ID=35580681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510026267 Expired - Fee Related CN1706449B (en) | 2005-05-27 | 2005-05-27 | Compound preparation of parasitic loranthus and mistletoe and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1706449B (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055639C (en) * | 1995-12-22 | 2000-08-23 | 黄登保 | Glossy ganoderma pill |
| CN1283265C (en) * | 2001-05-30 | 2006-11-08 | 张之道 | Compound medicine for treating dyspneic cough and its production process |
-
2005
- 2005-05-27 CN CN 200510026267 patent/CN1706449B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1706449B (en) | 2010-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN111097040A (en) | Antiviral lung-heat clearing peptide | |
| Mikaeili et al. | Antifungal activities of Astragalus verus Olivier. against Trichophyton verrucosum on in vitro and in vivo guinea pig model of dermatophytosis | |
| CN101032547A (en) | Anti-inflammatory and antivirotic medicine composition | |
| US7850998B2 (en) | Method of treating viral conditions | |
| US7842317B2 (en) | Method of treating viral conditions | |
| CN1308030C (en) | Medicine combination containing valid part of Ruyi Jinhuangsan and its preparing method | |
| CN1785384A (en) | Chinese medicinal composition for treating tuberculosis and its preparation method | |
| CN1799597A (en) | Application of Chinese medicinal composition in preparation of medicine for treating gynecological inflammation | |
| US20110104302A1 (en) | Composition and method for treating viral conditions | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN108785383B (en) | Antibacterial gynecological external medicine composition and preparation method and application thereof | |
| CN1706449B (en) | Compound preparation of parasitic loranthus and mistletoe and preparing method thereof | |
| CN109197917A (en) | The Chinese medicine compound prescription conditioning liquid and its preparation method and application for preventing and treating hand-foot-and-mouth disease | |
| CN1283391A (en) | Extracted liquor for disinfection | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN111000919A (en) | Application of ethanol extract of evodia lepta in preparation of medicine for treating sepsis | |
| CN1876044A (en) | A Chinese medicinal composition for treating infant fever caused by exogenous pathogen and preparation method thereof | |
| CN1231242C (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN1095377C (en) | Medicine for treating skin ringworm and dermatitis and preparation process | |
| CN116211926B (en) | Application of Jingfeng preparation in preparing anti-helicobacter pylori medicine | |
| CN100344319C (en) | Chinese medicine composition for treating urogenital system disease and its preparing method and use | |
| CN1706448A (en) | Compound Chinese medicine comprising parasitic loranthus and mistletoe and its use | |
| CN107296858B (en) | Antibacterial infection pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101117 Termination date: 20110527 |